Prostate Health Market 2022 Outlook, Current and Future Industry Landscape Analysis 2032

  • Due to significant growth in the geriatric population and a large target patient population, prostate cancer is expected to account for the largest share of the prostate health market based on disease indication.
  • Neurostimulation devices are anticipated to have the highest prostate health market share in the type market.
  • Attributing to the strong presence of hospital pharmacies around the world and the convenience offered by hospital pharmacies, the hospital pharmacies segment is projected to lead the prostate cancer treatment market.
  • The crucial factor for Asia-Pacific’s market growth can be credited to the rapidly growing patient population for benign prostatic hyperplasia in the region, particularly in Japan, China, South Korea, Hong Kong, and Taiwan.
  • The first commercial production of Axumin (fluciclovine) in Italy was announced by Blue Earth Diagnostics, with the first Italian patients being dosed.
  • Myovant partnered with Pfizer to commercialize Orgovyx (relugolix), a prostate cancer drug.
  • In the United States, Dr Reddy introduced generic Abiraterone Acetate Tablets USP, 250 mg, which is a therapeutic equivalent generic version of Zytiga (abiraterone acetate) for prostate cancer.
Publicado en SEO en octubre 25 at 10:19
Comentarios (0)
No login
Inicie sesión o regístrese para enviar su comentario
Cookies on De Gente Vakana.
This site uses cookies to store your information on your computer.